MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Watson, C.
Right arrow Articles by Kenakin, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Watson, C.
Right arrow Articles by Kenakin, T.

Vol. 58, Issue 6, 1230-1238, December 2000

The Use of Stimulus-Biased Assay Systems to Detect Agonist-Specific Receptor Active States: Implications for the Trafficking of Receptor Stimulus by Agonists

Chris Watson, Grace Chen, Paul Irving, James Way, Wen-Ji Chen, and Terry Kenakin

Departments of Receptor Biochemistry (C.W., G.C., P.I., T.K.) and Molecular Sciences (J.W., W.-J.C.), Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina

The quantitative comparison of the relative potency of agonists is a standard method of receptor and agonist classification. If agonist potency ratios do not correspond in two given tissues, this is used as presumptive data to conclude that the receptors in those two tissues are different. This article presents data to show that a single receptor can demonstrate varying agonist potency ratios in different host cells. These data are described in terms of the production of more than one agonist-selective receptor active state and the interaction of these different active states with multiple G proteins in the membrane to produce cellular response. Stable host human embryonic kidney 293 cells with enhanced quantities of the respective Galpha -protein were created. Wild-type and Galpha -subunit enriched cells were then transiently transfected with human calcitonin receptor type 2 (hCTR2). Binding did not detect differences in the G protein-enriched cells versus wild-type cells. In contrast, functional studies did show differences between the host cell lines and Galpha -subunit enriched cell lines. The relative potency of eight calcitonin agonists was measured in studies of calcium fluorescence in transfected cells containing human calcitonin receptor type 2 by comparing pEC50 (-log molar concentration producing half-maximal response) values. In Galpha s-enriched cells, the relative order of potency of the agonists changed. The host-cell dependent differences in potency ratios ranged from 2-fold to more than 46-fold. This finding is not consistent with the idea that all of the agonists produce response in the same manner (i.e., through a common active state of the receptor). These data are consistent with the idea that these different agonists produce arrays of active states that differentially use G proteins. This idea is discussed in terms of the design of stimulus-bias assay systems to detect agonist-selective receptor active states with resulting potential for increased selectivity of agonists.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
L. Stanasila, J.-B. Perez, H. Vogel, and S. Cotecchia
Oligomerization of the {alpha}1a- and {alpha}1b-Adrenergic Receptor Subtypes: POTENTIAL IMPLICATIONS IN RECEPTOR INTERNALIZATION
J. Biol. Chem., October 10, 2003; 278(41): 40239 - 40251.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
M. Azzi, P. G. Charest, S. Angers, G. Rousseau, T. Kohout, M. Bouvier, and G. Pineyro
{beta}-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors
PNAS, September 30, 2003; 100(20): 11406 - 11411.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Wei, S. Ahn, S. K. Shenoy, S. S. Karnik, L. Hunyady, L. M. Luttrell, and R. J. Lefkowitz
Independent {beta}-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2
PNAS, September 16, 2003; 100(19): 10782 - 10787.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
B. D. Stout, W. P. Clarke, and K. A. Berg
Rapid Desensitization of the Serotonin2C Receptor System: Effector Pathway and Agonist Dependence
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 957 - 962.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
A. Christopoulos and T. Kenakin
G Protein-Coupled Receptor Allosterism and Complexing
Pharmacol. Rev., June 1, 2002; 54(2): 323 - 374.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Braun, M. Wunderlin, K. Spieth, W. Knochel, P. Gierschik, and B. Moepps
Xenopus laevis Stromal Cell-Derived Factor 1: Conservation of Structure and Function During Vertebrate Development
J. Immunol., March 1, 2002; 168(5): 2340 - 2347.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics